Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) Operating Expenses (2023 - 2026)

MBX Biosciences has reported Operating Expenses over the past 4 years, most recently at $27.3 million for Q1 2026.

  • Quarterly results put Operating Expenses at $27.3 million for Q1 2026, up 1748.47% from a year ago — trailing twelve months through Mar 2026 was $57.1 million (up 149.2% YoY), and the annual figure for FY2025 was $98.1 million, up 2075.62%.
  • Operating Expenses reached $27.3 million in Q1 2026 per MBX's latest filing, up from $25.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $27.3 million in Q1 2026 and bottomed at $363000.0 in Q4 2024.
  • Median Operating Expenses over the past 4 years was $2.3 million (2025), compared with a mean of $9.3 million.
  • The largest annual shift saw Operating Expenses plummeted 96.37% in 2024 before it soared 7006.06% in 2025.
  • Over 4 years, Operating Expenses stood at $10.0 million in 2023, then tumbled by 96.37% to $363000.0 in 2024, then skyrocketed by 7006.06% to $25.8 million in 2025, then rose by 5.7% to $27.3 million in 2026.
  • Business Quant data shows Operating Expenses for MBX at $27.3 million in Q1 2026, $25.8 million in Q4 2025, and $2.3 million in Q3 2025.